Infelctra®/CT-P13* has robust clinical data for switching patients from Remicade®† to Inflectra®/CT- P13*17,39,41-43,46,47,53-55.
EU and UK guidance supports switching from reference biologics to a biosimilar in appropriate patients13,57,59,60.
Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, and with patient awareness.